Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Wolska

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Clinical Chemistry|October 2, 2019
CommentaryAnna Wolska, Alan T Remaley
Frontiers in Oncology|April 10, 2023
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directionsAnna Wolska-Washer, Tadeusz Robak
Drug Safety|January 17, 2019
Safety and Tolerability of Antibody-Drug Conjugates in CancerAnna Wolska-Washer, Tadeusz Robak
Future Oncology (London, England)|August 22, 2019
Glasdegib in the treatment of acute myeloid leukemiaAnna Wolska-Washer, Tadeusz Robak
Clinical Chemistry|July 17, 2019
LDL Cholesterol: What Is the Best Way to Measure It?Anna Wolska, Alan T Remaley
Current Opinion in Cardiology|May 16, 2020
Measuring LDL-cholesterol: what is the best way to do it?Anna Wolska, Alan T Remaley
The Journal of Applied Laboratory Medicine|September 22, 2022
CRP and High-Sensitivity CRP: "What's in a Name?"Anna Wolska, Alan T Remaley
Expert Review of Hematology|March 17, 2022
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemiaAnna Wolska-Washer, Tadeusz Robak
Cancers|August 12, 2022
Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological MalignanciesAnna Wolska-Washer, Piotr Smolewski
Expert Opinion on Investigational Drugs|September 3, 2015
Potential breakthroughs with investigational drugs for hairy cell leukemiaTadeusz Robak, Anna Wolska, Pawel Robak
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Clinical Chemistry|October 2, 2019
CommentaryAnna Wolska, Alan T Remaley
Frontiers in Oncology|April 10, 2023
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directionsAnna Wolska-Washer, Tadeusz Robak
Drug Safety|January 17, 2019
Safety and Tolerability of Antibody-Drug Conjugates in CancerAnna Wolska-Washer, Tadeusz Robak
Future Oncology (London, England)|August 22, 2019
Glasdegib in the treatment of acute myeloid leukemiaAnna Wolska-Washer, Tadeusz Robak
Clinical Chemistry|July 17, 2019
LDL Cholesterol: What Is the Best Way to Measure It?Anna Wolska, Alan T Remaley
Current Opinion in Cardiology|May 16, 2020
Measuring LDL-cholesterol: what is the best way to do it?Anna Wolska, Alan T Remaley
The Journal of Applied Laboratory Medicine|September 22, 2022
CRP and High-Sensitivity CRP: "What's in a Name?"Anna Wolska, Alan T Remaley
Expert Review of Hematology|March 17, 2022
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemiaAnna Wolska-Washer, Tadeusz Robak
Cancers|August 12, 2022
Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological MalignanciesAnna Wolska-Washer, Piotr Smolewski
Expert Opinion on Investigational Drugs|September 3, 2015
Potential breakthroughs with investigational drugs for hairy cell leukemiaTadeusz Robak, Anna Wolska, Pawel Robak
Pageof 12